EP4743494A1 - Dosage schedule for therapies with bispecific anti-FR/C-MET antibodies - Google Patents

Dosage schedule for therapies with bispecific anti-FR/C-MET antibodies

Info

Publication number
EP4743494A1
EP4743494A1 EP24765209.2A EP24765209A EP4743494A1 EP 4743494 A1 EP4743494 A1 EP 4743494A1 EP 24765209 A EP24765209 A EP 24765209A EP 4743494 A1 EP4743494 A1 EP 4743494A1
Authority
EP
European Patent Office
Prior art keywords
therapies
bispecific anti
dosage schedule
met antibodies
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24765209.2A
Other languages
German (de)
French (fr)
Inventor
Roland Knoblauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/222,093 external-priority patent/US20250388681A2/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of EP4743494A1 publication Critical patent/EP4743494A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP24765209.2A 2023-07-14 2024-07-03 Dosage schedule for therapies with bispecific anti-FR/C-MET antibodies Pending EP4743494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/222,093 US20250388681A2 (en) 2022-07-14 2023-07-14 Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodes
PCT/IB2024/056510 WO2025017409A1 (en) 2023-07-14 2024-07-03 Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies

Publications (1)

Publication Number Publication Date
EP4743494A1 true EP4743494A1 (en) 2026-05-20

Family

ID=92633078

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24765209.2A Pending EP4743494A1 (en) 2023-07-14 2024-07-03 Dosage schedule for therapies with bispecific anti-FR/C-MET antibodies

Country Status (2)

Country Link
EP (1) EP4743494A1 (en)
WO (1) WO2025017409A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP2011507519A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
ES2831374T3 (en) 2012-11-21 2021-06-08 Janssen Biotech Inc Bispecific EGFR / c-Met Antibodies
NZ730012A (en) 2014-10-13 2019-06-28 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
US20250388681A2 (en) * 2022-07-14 2025-12-25 Janssen Biotech, Inc. Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodes

Also Published As

Publication number Publication date
WO2025017409A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
EP3941944A4 (en) BISPECIFIC CLAUDIN-6 ANTIBODIES
MA55305A (en) ANTI-V BETA 17/ANTI-CD123 BISPECIFIC ANTIBODIES
PL3723858T3 (en) Fixaxfx bispecific antibody with common light chain
KR102587633B9 (en) Interleukin-31 monoclonal antibody for veterinary use
AR081750A1 (en) ANTI-CD40 ANTIBODIES
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
SG11202102765RA (en) Humanised anti-n-truncated amyloid beta monoclonal antibody
IL289252A (en) Bispecific antibody
EP4337228A4 (en) Dosing plans for cancer immunotherapy
MA55705A (en) BISPECIFIC ANTIBODIES
EP4271475A4 (en) ACCELERATOR FOR FLASH RADIOTHERAPY
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3
IL286918A (en) Bispecific antibody
IL311043A (en) Anti-IL---11RA antibodies
EP4001306C0 (en) Humanized Monoclonal Anti-VeGF Antibody
IL318216A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL290050A (en) Bispecific antibody
IL282742A (en) A monoclonal antibody that binds uniquely to CD20
MX2017011480A (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof.
EP4422685A4 (en) ANTI-CTLA-4 ANTIBODY DOSING SCHEMES
EP4472639A4 (en) BISPECIFIC ANTIBODY THERAPIES
EP4097139A4 (en) BISPECIFIC PLAP-CD3-EPSILON ANTIBODIES
EP4397685A4 (en) HUMANIZED ANTI-CD3 ANTIBODY
EP4126968A4 (en) EFFECTIVE DOSE FOR A HER2 BISPECIFIC ANTIBODY
GB201820006D0 (en) Humanised anti-IL17BR antibody

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE